Trial · NCT07895524
A Clinical Trial of MK-8690 in Participants With Rheumatoid Arthritis (MK-8690-004)
NCT07895524, Phase 2, Not yet recruiting, Merck Sharp & Dohme LLC
3 sourcestrials-2026-11-12-0.5.0
Download JSON
Cite this record
ConductScience Library. A Clinical Trial of MK-8690 in Participants With Rheumatoid Arthritis (MK-8690-004). Trials, record NCT07895524. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07895524
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Clinical Trial of MK-8690 in Participants With Rheumatoid Arthritis (MK-8690-004)
- NCT number
- NCT07895524
- Status
- Not yet recruiting
- Phases
- Phase 2
- Enrollment
- 60 participants, estimated
- Lead sponsor
- Merck Sharp & Dohme LLC
- Conditions
- Rheumatoid Arthritis
- Interventions
- MK-8690, Placebo, Methotrexate (MTX)
- First posted
- 2026-10-26
- Last updated
- 2026-10-26
Source ClinicalTrials.gov
Registered outcomes10
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Percentage of Participants Achieving American College of Rheumatology 50% Response Criteria (ACR50) at Week 12 | Week 12 | ACR response is a well-established composite measure used in clinical trials to evaluate clinical response in rheumatoid arthritis (RA). ACR50 response is defined as 50% or greater improvement in tender joint count (TJC) based on 68 joints, swollen joint count (SJC) based on 66 joints, and ≥3 of the 5 remaining components of Health Assessment Questionnaire-Disability Index (HAQ-DI), Physician Global Assessment of Disease Activity (PGA), Patient Global Assessment of Disease Activity (PtGA), Patient Assessment of Pain Severity, and high-sensitivity C-reactive protein (hsCRP). ACR50 is an accepted measure by the FDA to demonstrate reduction in RA disease activity and is defined as the proportion of participants achieving 50% improvement in the composite measure. The percentage of participants achieving ACR50 at Week 12 will be presented. |
| Secondary | Number of Participants Who Experience One or More Adverse Events (AEs) | Up to approximately 70 weeks | An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who experience 1 or more AEs will be presented. |
| Secondary | Number of Participants Who Discontinue Study Intervention Due to an AE | Up to approximately 48 weeks | An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who discontinue study intervention due to an AE will be presented. |
| Secondary | Percentage of Participants Achieving American College of Rheumatology 20% Response Criteria (ACR20) at Week 12 | Week 12 | ACR20 response is defined as 20% or greater improvement in TJC based on 68 joints, SJC based on 66 joints, and ≥3 of the 5 remaining components of HAQ-DI, PGA, PtGA, Patient Assessment of Pain Severity, and hsCRP. ACR20 is an accepted measure by the FDA to demonstrate reduction in RA disease activity and is defined as the proportion of participants achieving 20% improvement in the composite measure. The percentage of participants achieving ACR20 at Week 12 will be presented. |
| Secondary | Percentage of Participants Achieving American College of Rheumatology 70% Response Criteria (ACR70) at Week 12 | Week 12 | ACR70 response is defined as 70% or greater improvement in TJC based on 68 joints, SJC based on 66 joints, and ≥3 of the 5 remaining components of HAQ-DI, PGA, PtGA, Patient Assessment of Pain Severity, and hsCRP. ACR70 is an accepted measure by the FDA to demonstrate reduction in RA disease activity and is defined as the proportion of participants achieving 70% improvement in the composite measure. The percentage of participants achieving ACR70 at Week 70 will be presented. |
| Secondary | Percentage of Participants Achieving Low Disease Activity (LDA) based on Disease Activity Score 28 Using C-Reactive Protein (DAS28-CRP) at Week 12 | Week 12 | The DAS28-CRP is a continuous composite measure of RA activity that includes the following components: * TJC (out of a total of 28 joints) * SJC (out of a total of 28 joints) * hsCRP * PtGA The 28 anatomical joints for inclusion in the TJC and SJC scoring are the shoulders, elbows, wrists, first through fifth metacarpophalangeals, second through fifth proximal interphalangeals, thumb interphalangeals, and knees. The DAS28-CRP score ranges from 0 to 10, with higher scores indicating a higher degree of disease activity. LDA is indicated by a DAS28-CRP score of ≤3.2. The percentage of participants achieving LDA at Week 12 will be presented. |
| Secondary | Change from Baseline in DAS28-CRP | Baseline and at designated timepoints up to Week 52 | The DAS28-CRP is a continuous composite measure of RA activity that includes the following components: * TJC (out of a total of 28 joints) * SJC (out of a total of 28 joints) * hsCRP * PtGA The 28 anatomical joints for inclusion in the TJC and SJC scoring are the shoulders, elbows, wrists, first through fifth metacarpophalangeals, second through fifth proximal interphalangeals, thumb interphalangeals, and knees. The DAS28-CRP score ranges from 0 to 10, with higher scores indicating a higher degree of disease activity. The change from Baseline at designated timepoints up to Week 52 in the DAS28-CRP will be presented. |
| Secondary | Percentage of Participants Achieving LDA based on DAS28-CRP | At designated timepoints up to Week 52 | The DAS28-CRP is a continuous composite measure of RA disease activity that includes the following components: * TJC (out of a total of 28 joints) * SJC (out of a total of 28 joints) * hsCRP * PtGA The 28 anatomical joints for inclusion in the TJC and SJC scoring are the shoulders, elbows, wrists, first through fifth metacarpophalangeals, second through fifth proximal interphalangeals, thumb interphalangeals, and knees. The DAS28-CRP score ranges from 0 to 10, with higher scores indicating a higher degree of disease activity. Remission is indicated by a DAS28-CRP score of \<2.6 and LDA by a DAS28-CRP score of ≤3.2. The percentage of participants achieving LDA at designated timepoints up to Week 52 based on DAS28-CRP will be presented. |
| Secondary | Percentage of Participants Achieving Clinical Remission Based on DAS28-CRP | At designated timepoints assessed up to Week 52 | The DAS28-CRP is a continuous composite measure of RA disease activity that includes the following components: * TJC (out of a total of 28 joints) * SJC (out of a total of 28 joints) * hsCRP * PtGA The 28 anatomical joints for inclusion in the TJC and SJC scoring are the shoulders, elbows, wrists, first through fifth metacarpophalangeals, second through fifth proximal interphalangeals, thumb interphalangeals, and knees. The DAS28-CRP score ranges from 0 to 10, with higher scores indicating a higher degree of disease activity. Remission is indicated by a DAS28-CRP score of \<2.6 and LDA by a DAS28-CRP score of ≤3.2. The percentage of participants achieving clinical remission at designated timepoints assessed up to Week 52 based on DAS28-CRP will be presented. |
| Secondary | Change From Baseline in the HAQ-DI Score | Baseline and Week 12 | HAQ-DI is measure of physical function in RA clinical trials and is a 20-item questionnaire completed by the participant. The measure includes 8 domains assessing "dressing and grooming," "arising," "eating," "walking," "hygiene," "reach," "grip," and "activities." Participants respond on a 4-point scale ranging from 0 = "without ANY difficulty" to 3 = "UNABLE to do." The measure also captures the use of aids or devices and need for help from another person. The overall disability score is a summation of the highest score from each domain divided by the number of domains completed and ranges from 0 to 3 (worst disability). Clinically meaningful improvement in HAQ-DI for RA has been determined to be ≥0.22 points. The change from Baseline to Week 12 in the HAQ-DI will be presented. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07895524
GET https://conductscience.org/api/trials/v1/NCT07895524/registered